Uptake of the RSVpreF vaccine during pregnancy: associations with socioeconomic status, prenatal care utilization, and maternal risk factors.
Respiratory syncytial virus (RSV) is a leading cause of infant respiratory illness. In August 2023, the RSV protein-based vaccine (RSVpreF) became the first maternal vaccine approved in the United States to prevent RSV infection in newborns. The study aims to estimate RSVpreF vaccine uptake during its first RSV season...